Question · Q4 2025
Michael Ward asked Tony Cheng to elaborate on specific regions or product lines that appear incrementally attractive for RGA in the current year. He also inquired about U.S. traditional mortality trends, specifically if there was any insight into January's flu season activity following a solid Q4 result.
Answer
President and CEO Tony Cheng described a rich and diverse pipeline, highlighting strong momentum in Asia (product development, financial solutions), the UK longevity market, and the U.S. (industry realignment, biometric/underwriting-driven wins). EVP and Global Chief Risk Officer Jonathan Porter stated it's too early to predict the final flu season outcome but noted encouraging declining trends in population-level flu activity and that Q4 mortality experience was in line overall.
Ask follow-up questions
Fintool can predict
RGA's earnings beat/miss a week before the call


